{
  "id": 1070492,
  "title": "Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock",
  "url": "https://urgent.news/2026/08/15/avalo-therapeutics-cmo-mittie-doyle-sells-13-580-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-15T15:31:12.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/avalo-therapeutics-cmo-mittie-doyle-sells-13580-in-stock-93CH-4861804"
  },
  "original_language": "en",
  "account": "Chief Medical Officer Mittie Doyle of Avalo Therapeutics, Inc. (NASDAQ: AVTX) sold 679 shares of the company's common stock on August 10, 2026. The transaction valued at $13,580 was executed at $20.00 per share. Despite being close to its sale price, Avalo Therapeutics shares are currently perceived as overvalued by InvestingPro analysis. The company has experienced a 117% return over the past year, as per InvestingPro data. Concurrently, Doyle acquired 679 shares by exercising stock options at $8.04 each, totaling $5,459. These transactions were conducted under a pre-existing Rule 10b5-1 trading plan adopted on November 13, 2025. The exercised options vest 25% on January 28, 2026, with the remaining 75% vesting monthly over the next three years, contingent on Doyle's continued employment. After these activities, Doyle directly holds 51,776 shares and retains 114,413 stock options. Avalo Therapeutics has recently been added to the Russell 2000 and 3000 indexes, affirming its status among the largest U.S. publicly traded companies. The company also appointed Ron Philip to its board of directors, bringing extensive biopharmaceutical experience to the role. Analyst updates have assigned Avalo Therapeutics an Overweight rating, focusing on recent Phase 2 data for their lead program in hidradenitis suppurativa.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Avalo Therapeutics CSO Jennifer Riley sells $52,012 in stock",
        "url": "https://urgent.news/2026/08/15/avalo-therapeutics-cso-jennifer-riley-sells-52-012-in-stock",
        "published": "2026-08-15T15:31:09.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}